Skip to content
Open·Synced from source July 16, 2026

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Dec 17, 2025
Closes
Nov 15, 2027 (in 487 days)
Last verified
Jul 16, 2026

Classification and identifiers

Solicitation number
PAR-25-336
Assistance listing (CFDA)
93.395

Amount

Amount not published by the funder

Who can apply

Local governmentsNonprofits (non-501c3)For-profitsHousing authoritiesSmall businessCounty governments

Local government agencies and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as ...

About this opportunity

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI...

Refine this search